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Introduction
Pure immature teratoma is the second most common
germ cell malignancy of all ovarian cancers; it represents
< 1%.1–4 However, in women younger than 20 years, it
amounts to 10–20% of all ovarian malignancies, and
contributes 30% of the ovarian cancer mortalities in this
age group.5 About 50% of pure immature teratomas
of the ovary occur in women between the ages of 10
and 20 years; hence, treatment to preserve their future
fertility should be considered because the majority of
ovarian germ cell tumors (OGCT) are curable with the
aid of conservative surgery and follow-up combination
chemotherapy.6,7 The first report of a successful preg-
nancy following conservative surgery and chemother-
apy for advanced-stage immature teratoma appeared
in 1989.8 With further advanced development of
chemotherapy and more understanding of the disease
course of ovarian immature teratoma, fertility-preserving
surgery followed by multiagent chemotherapy has
become a choice in patients with immature teratoma
of the ovary. The following case report describes a
woman with advanced immature teratoma of the ovary
that had been treated with intensive conservative sur-
gery and multiagent chemotherapy, who subsequently
successfully delivered a baby.
Case Report
A 29-year-old woman, who had been diagnosed with
and treated for ovarian tumor at 13 years of age,
delivered a healthy baby. The initial treatment was
unilateral salpingo-oophorectomy and wedge resec-
tion of the contralateral ovary. The final pathology
showed ovarian immature teratoma, grade 3. The pa-
tient then received 6-course multiagent chemother-
apy, including 3-day cisplatin 20 mg/m2 + vinblastine
1.5 mg/m2 + bleomycin 10 mg/m2 (PVB), because of
the presence of the immature teratoma, grade 3, uncer-
tain stage (suspicious initial stage of at least Interna-
tional Federation of Gynecology and Obstetrics [FIGO]
stage Ic) and incomplete staging surgery. Laparotomy
was performed after the initial 6-course chemotherapy
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because imaging study showed residual tumors within
the cul-de-sac and abdominal cavity. Tumor excision
and complete staging surgery with fertility-preservation
were performed. Pathology showed the residual
tumor within the cul-de-sac to be an immature ter-
atoma, grade 1, while the others, such as multiple sites
of the random biopsies, were negative. Then, addi-
tional 6-course chemotherapy with a 3-day etoposide
100 mg/m2 and cisplatin 20 mg/m2 (EP) regimen
was prescribed.
Menstruation occurred 1 year after complete ther-
apy (at the age of 15 years). No menstruation disor-
der was recorded during the follow-up. The patient
married at the age of 26 and underwent 3 cycles of
clomiphene for ovarian induction due to 2-year sub-
fertility but in vain. However, she became pregnant
spontaneously without the assistance of a reproduc-
tive technique and delivered a healthy baby at the age
of 29 years.
Discussion
Immature teratomas are solid tumors containing imma-
ture or embryonic tissues and account for approximately
20% of all malignant OGCT.1–3 Immature neuroepi-
thelium is the predominant immature tissue found and
can be used for tumor grading, such as grades 1, 2
and 3, when immature neuroepithelium occupies 0 
or 1, ≤ 3, or ≥ 4 low-power fields (40×) per section,
respectively.1
The prognosis of immature teratomas is governed
by grade and stage.9,10 For example, cases of grade 1
in stage I might have up to a 94% survival rate, whereas
cases of grade 2 or 3 in stage I might drop to an 82%
chance of survival.9 Grade also contributes to the
recurrence rate, with higher grades having a higher
recurrence rate.10
Treatment is dependent on the age of the patient
and the specific tumor type. Although surgery is the
most common form of treatment for immature ter-
atoma, extensively destructive surgery, including total
hysterectomy, bilateral salpingo-oophorectomy, omen-
tectomy, lymph node sampling and appendectomy is
seldom considered for immature teratoma, except for
those patients who have completed their fertility. There-
fore, fertility-preserving surgery is the treatment of
choice for younger women, because postoperative adju-
vant chemotherapy has dramatically improved the prog-
nosis of immature teratoma. In the present case, we
further confirmed this concept.
Four controversial issues brought to our atten-
tion in this case should be mentioned: (1) the best
combination chemotherapy regimen for malignant
OGCT; (2) the role of second-look operation or sec-
ondary operation for malignant OGCT; (3) the con-
sideration of ovarian function and future fertility in
cancer patients; and (4) the safety of chemotherapy.
One of the great triumphs in the field of gyneco-
logic oncology has been the attainment of cure in the
vast majority of young patients with malignant OGCT.11
Smith and Rutledge12 had begun using the combination
of vincristine, dactinomycin, and cyclophosphamide
(VAC), with cure rates therefore unimaginable. The
demise of the VAC regimen as standard therapy, how-
ever, was essentially sealed by the introduction of
PVB,13 and subsequent reports that revealed that 
VAC was very active for patients with stage I disease,
but rather ineffective for those with advanced-stage
tumors.14 Culine et al15 added etoposide to VPB and
showed promising results in malignant OGCT; how-
ever, toxicity was very high. Because equal efficacy and
less toxicity favored the combination of bleomycin,
etoposide and cisplatin (BEP) as standard treatment
for malignant OGCT in the 1990s, subsequent reports
further confirmed the BEP regimen as first-line therapy
for OGCT.16–19 To further decrease the toxicity of 
the BEP regimen, the following modifications were
reported in the literature, including carboplatin used as
a replacement for cisplatin in the BEP regimen and a 
3-day modification protocol for the BEP regimen.20,21
Taken together, a postoperative 3-cycle or 4-cycle 
3-day BEP (standard-dose cisplatin) regimen should 
be administered in patients with ovarian immature ter-
atoma after fertility-preserving surgery.22,23
Is there a place for second-look operation in
OGCT? In our case, due to the initial incomplete sur-
gery, the uncertain stage, teratoma component and of
most importance, the visible “residual” tumor in the
imaging study, all of which fulfilled the suggested cri-
teria for second-look operation in OGCT in the liter-
ature,24,25 laparotomy might have been a better choice.
The following conditions, including an incompletely
resected tumor that contains a teratoma,24 or persist-
ent radiologic abnormalities along with normal serum
tumor markers at the end of chemotherapy,25 could
lead to a consideration of second-look laparotomy or
re-exploratory laparotomy.
Since patients with OGCT are young, what is the
effect of chemotherapy on ovarian function or future
fertility? A recent review addressed various views to
expand possibilities for fertility preservation in cancer
patients,26 including (1) the number of women who
become infertile after cancer treatment is unknown;
(2) infertility can affect patients with any cancer treated
with radiation therapy or chemotherapy, but the greatest
risks are from chemotherapy involving alkylating agents
or whole-body irradiation;27 (3) surgeries that are com-
mon for ovarian and cervical cancers can also compro-
mise fertility; and of most importance (4) none of the
fertility preservation methods is clearly effective because
all of them tend to be expensive, unless there is a
research protocol that pays for medications or proce-
dures.26 In our case, the main therapies that would
affect the gonadotoxicity were destruction of the ovary,
such as unilateral oophorectomy and partial oophorec-
tomy of the contralateral ovary or chemotherapy. Since
a removed ovary cannot be recovered, the preserva-
tion of future fertility should focus on the topic of
chemotherapy, which may induce gonadotoxicity.
Chemotherapy-induced gonadotoxicity is almost always
irreversible.28 Histologic sections of the ovary after
treatment with cytotoxic drugs known to cause ovar-
ian failure show a spectrum of changes ranging from
decreased numbers of follicles to absent follicles to
fibrosis.29 The exact incidence of premature ovarian
failure after chemotherapy is difficult to establish
because many factors contribute to ovarian failure. The
most important parameters are the age of the patient,
the drug class, and the cumulative dose of the drug.
The risk of gonadal damage increases as the age of 
the woman increases and is most likely caused by the
presence of a lower number of remaining oocytes com-
pared with the younger patient. Cytotoxic chemother-
apeutic agents are not equally gonadotoxic,29 and the
most toxic drugs are alkylating agents.26 These drugs
may impair follicular maturation or deplete primordial
follicles. Temporary amenorrhea will result when matur-
ing follicles are destroyed by cytotoxic drugs, whereas
permanent amenorrhea or premature ovarian failure
is seen when all primordial follicles are destroyed.29
A recent review30 indicated that if chemotherapy is
administered to patients with OGCT, including imma-
ture teratoma, there is a risk of ovarian failure up to
approximately 30%.30–35 Other patients will subse-
quently develop premature menopause. However, most
patients with OGCT may be treated with fertility-
sparing surgery followed by chemotherapy with preser-
vation of the fertility potential. Because the cure rates
approach 100% for those with early-stage disease and
are ≥75% for patients with advanced-stage disease, the
opportunity for future childbearing is excellent. The
outcomes of 5 large studies in terms of ovarian func-
tion and pregnancies following definitive treatment
with an incidence of normal menstruation ranged from
68% to 99%, and pregnancy numbers ranged from
19.7% to 72.5%.31–35 As noted, several successful preg-
nancies have been reported after primary surgery plus
combination chemotherapy,31–35 similar to our case.
Considering the safety of chemotherapy and since
lung toxicity can occur in chemotherapy containing
bleomycin, which shows cumulative toxicity, the
chemotherapy regimen followed by the secondary
operation in our case did not include bleomycin.
Taken together, irrespective of subtype and stage,
fertility-preserving surgery should be the first choice for
young patients with malignant OGCT if they have not
completed their family. Fertility seems to be only mar-
ginally affected by treatment. Miscarriages are in the
expected range for the general population. The malfor-
mation rate is slightly higher than in the general popula-
tion, but no significant difference was seen between
patients who did and did not receive chemotherapy.1
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